质子治疗与调强放射治疗在头颈部鳞状细胞癌肿瘤学结局中的比较
该研究基于台湾癌症登记数据库,纳入2015至2019年接受根治性放疗的头颈部鳞状细胞癌患者,比较质子治疗与调强放射治疗的肿瘤学结局。全国回顾性队列共60,485例,倾向评分匹配后分析982例,质子治疗与更低的全因死亡、肿瘤特异性死亡及局部区域复发风险相关。
要点
- 匹配后982例分析显示,质子治疗与更低的全因死亡风险相关(aHR=0.43)。
- 质子治疗与更低的肿瘤特异性死亡风险相关(aHR=0.44)。
- 质子治疗与更低的局部区域复发风险相关(aHR=0.61)。
核心结论
- 在头颈部鳞状细胞癌患者中,与调强放射治疗相比,质子治疗与更好的总生存、肿瘤特异性生存及更低的局部区域复发率相关。
- 作者认为这些结果为临床医生和患者在选择头颈部鳞状细胞癌放疗方式时提供了有价值的证据。
研究设计与样本
- 全国回顾性头颈部鳞状细胞癌队列研究,数据来自台湾癌症登记数据库,纳入2015至2019年接受根治性放疗的患者。
- 研究涉及台湾3家具备质子治疗的中心和17家开展调强放射治疗的医疗中心级机构。
- 患者按治疗方式分为两组:第1组接受调强放射治疗,第2组接受质子治疗。
- 采用3:1倾向评分匹配以减少潜在混杂因素影响,并使用Cox比例风险模型评估肿瘤学结局。
主要发现
- 研究共纳入60,485例头颈部鳞状细胞癌患者,发现质子治疗与更好的总生存、肿瘤特异性生存及更低的局部区域复发率相关。
- 倾向评分匹配后分析982例,各因素均衡良好。
- 质子治疗是全因死亡、肿瘤特异性死亡和局部区域复发的显著预测因素。
- 接受质子治疗的患者全因死亡风险显著低于调强放射治疗者(校正风险比aHR=0.43)。
- 接受质子治疗的患者肿瘤特异性死亡风险显著低于调强放射治疗者(aHR=0.44),局部区域复发风险亦显著更低(aHR=0.61)。
关键数值与推荐
- 全因死亡的校正风险比:质子治疗组对比调强放射治疗组aHR=0.43。
- 肿瘤特异性死亡的校正风险比:质子治疗组对比调强放射治疗组aHR=0.44。
- 局部区域复发的校正风险比:质子治疗组对比调强放射治疗组aHR=0.61。
- 匹配后分析样本量982例;匹配前队列60,485例。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To compare the oncologic outcomes between proton therapy and intensity-modulated radiation therapy (IMRT) for head and neck squamous cell carcinoma (HNSCC) patients undergoing curative radiotherapy (RT). EXPERIMENTAL DESIGN: We studied HNSCC patients who underwent curative-intent RT from 2015 to 2019, comparing the oncologic outcomes of proton therapy and IMRT. Our national retrospective HNSCC cohort study involved three institutes with proton therapy and 17 institutes (medical center levels) with IMRT in Taiwan. We utilized the Taiwan Cancer Registry Database to collect medical data for this study. We classified patients into two groups based on treatment method: Group 1 received IMRT, while Group 2 received proton therapy. 3:1 propensity score matching was performed to minimize the impact of potential confounders. Cox proportional hazards models were used to evaluate oncologic outcomes. RESULTS: This study of 60,485 patients with HNSCC found that proton therapy was associated with better overall and cancer-specific survival and lower locoregional recurrence rates than IMRT. After matching, 982 patients were analyzed, with well-balanced factors. Proton therapy was a significant predictor of all-cause mortality, cancer-specific death, and locoregional recurrence (LRR). Patients who received proton therapy had significantly lower risks of all-cause mortality (adjusted hazard ratio, aHR=0.43), cancer-specific death (aHR=0.44), and LRR (aHR=0.61) than those who received IMRT. CONCLUSION: Proton therapy is associated with superior outcomes in terms of overall survival, cancer-specific survival, and locoregional recurrence rates compared to IMRT in patients with HNSCC. These results provide valuable evidence for clinicians and patients in decision-making regarding the choice of radiation therapy for HNSCC.
引用
- Chang CL, Lin KC, Chen WM, et al. Comparing the Oncologic Outcomes of Proton Therapy and Intensity-Modulated Radiation Therapy for Head and Neck Squamous Cell Carcinoma. Radiother Oncol. 2023. PMID: 39492511. doi:10.1016/j.radonc.2023.109971
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。